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ABSTRACT
Ondansetron HCl is a potent, highly selective 5-HT3
receptor-antagonist used to prevent nausea and
vomiting, mainly in patients undergoing chemotherapy
and radiation treatments. The aim of present work was
to formulate, evaluate and optimize gastro-retentive
tablet of Ondansetron HCl which would be
advantageous, that can provide prolong gastric
retention and increase efficacy of the dosage form. In
formulation optimization, different formulation of
HPMC polymer, NaCMC and NaHCO3 were studied
with help of 32 full factorial designs. It was found that
HPMC K4M with concentration 40%, NaCMC 5%
and NaHCO3 with 17% concentrations showed good
sustained and floating ability and it releases 94.51%
drug within 24 hrs. During study of effect of process
parameters, it was concluded that release of drug
decreases with decreasing granular size. The drying
time (10 and 20 min) and drying temperature (40° and
50°C), does not have any significant effect on the
release profile of drug.
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INTRODUCTION
Chemotherapy-induced nausea and vomiting
(CINV) is a significant adverse side effect for patients
receiving chemotherapy. Patients treated with
chemotherapy may experience anticipatory, acute, and
delayed nausea and vomiting. The choice of
antiemetic therapy is a vital part of preventing these
symptoms and enhancing patient satisfaction. In
addition, consideration of the emetogenic potential of
chemotherapy agents is important for appropriate
prescribing of antiemetics. This program will review
the pathophysiology of CINV, antiemetic
pharmacology, and appropriate guidelines for
prophylaxis of CINV.
Ondansetron is used to prevent the nausea and
vomiting that may occur after therapy with anticancer
medicines (chemotherapy) or radiation, or after
surgery. Ondansetron hydrochloride has a short
biological half-life (3.5 ± 1.2 hours) and 62 %
absolute bioavailability. Dose of the drug is 0.15
mg/kg, 3 times/day beginning 30 minutes prior to
chemotherapy or 0.45 mg/kg once daily or 8-10 mg 1-
2 times/day or 24 mg or 32 mg once daily.[2]
To reduce frequency of administration of the drug and
for patient compliance, gastro retentive tablet of
Ondansetron HCl were prepared in order to release
loading dose as well as maintenance dose of
Ondansetron HCl through increasing residence time in
stomach with the help of floating mechanisms. Tablets
were prepared by wet granulation method using
different polymer like HPMC, Klucel HXF, Carbopol
934P, and NaCMC. Sodium bicarbonate used as a gas




Ondansetron HCl was obtained as a gift sample from
Lincoln Pharmaceuticals Ltd, Ahmedabad, India.
HPMC K4M was obtained as gift sample from Jaxani
Pharma, Ahmedabad, India. Klucel HXF was obtained
from cadila Pharma, Ahmedabad. Carbopol 934P,
Sodium carboxy methyl cellulose, Sodium bicarbonate
was obtained from S. D. Fine chemicals, Mumbai,
India. All other ingredients were of laboratory grade.
Methods
Preparation of standard calibration curve of
ondansetron HCL
Ondansetron HCl (10 mg) was dissolved in 0.1 N HCl
(PH=1.2) and volume was made up to 100 ml in 100
ml volumetric flask. This solution (100 g /ml) was
further diluted with 0.1 N HCl to obtain solution of 5
to 25 g /ml. Absorbance of each solution was
measured at 310 nm using Shimadzu UV-1700
UV/VIS double beam spectrophotometer and 0.1 N
HCl as reference standard. The standard calibration
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Calculation of total dose and theoritical drug
release profile [3,4]
The pharmacokinetic parameters of Ondansetron HCl
were utilized for the calculation of theoretical drug
release profile for 24 hrs dosage form. The immediate
release part (loading dose) of Ondansetron HCl was
calculated using following equation.
F
VdCssIRD 
Where, Css is steady-state plasma concentration, Vd is
volume of distribution, and F is fractional
bioavailability. The total dose of Ondansetron HCl
required for 24 hrs release profile was calculated using
following equation.
Dose = Immediate release part {1 +
(0.693 * t/t1/2)}
Drug excipients interaction study [5]
The pure drug, Ondansetron HCl and a mixture of
drug with the polymer HPMC K4M and NaCMC was
examined by DSC using a shimadzu DSC-50
differential scanning calorimeter at 20° C/min over a
temperature range of 50° - 300° C.
Measurement of viscocity of polymer [6]
To prepare 2% (w/v) an aqueous solution, it is
recommended that hypromellose is dispersed and
thoroughly hydrated in about 20–30% of the required
amount of water. The water should be vigorously
stirred and heated to 80–90°C, and then the remaining
hypromellose should be added. Sufficient cold water
should then be added to produce the required
volume.The viscosity of solution was measured using
Brookfield digital viscometer.
Optimization of HPMC concentration using 32 full
factorial design
A 32 randomized full factorial design was utilized in
the present study. In this design two factors were
evaluated, each at three levels, and experimental trials
were carried out at all nine possible combinations. The
factors were selected based on preliminary study. The
Content of HPMC (X1) and Viscosity of HPMC (X2)
were selected as independent variables. The time
required for 50% drug release (t50%), release at 24hrs
(Q24hrs) and similarity factor f2 were selected as
dependent variables.
In vitro dissolution study [1]
The release rate of Ondansetron HCl from sustained
release tablets was determined using United State
Pharmacopoeia (USP) XXIV dissolution testing
apparatus II (paddle method). The dissolution test was
performed using 900 ml of 0.1 N HCl (PH=1.2), at 37
 0.5C and 50 rpm.
Comparison of dissolution profile[7]
The similarity factor (f2) given by SUPAC guidelines
for modified release dosage form was used as a basis
to compare dissolution profile. The dissolution
profiles are considered to be similar when f2 is
between 50 and 1007. The dissolution profiles of
products were compared using f2 This similarity factor





















Where, n is the number of dissolution time and Rt and
Tt are the reference and test dissolution values at time
t.
In vitro buoyancy study [8]
The tablets were placed in 100 ml beaker containing
0.1 N HCl (PH=1.2). The time required for the tablets,
to rise to the surface and float, was determined as
floating lag time.
Optimization of NaCMC & NaHCO3
A 32 randomized full factorial design was utilized in
the present study. In this design two factors were
evaluated, each at three levels, and experimental trials
were carried out at all nine possible combinations. The
Content of NaCMC (X1) and Content of NaHCO3
(X2) were selected as independent variables. The time
required for 50% drug release (t50%), release at 24hrs
(Q24hrs) and similarity factor f2 were selected as
dependent variables.
Evaluation of physical parameters of prepared
tablets [9]
Prepared gastro retentive tablets of Ondansetron HCl
tablet were evaluated for various parameters like,
weight variation test, hardness, friability etc.
Kinetic modeling and mechanism of drug release
[10]
Data obtained form In vitro drug release studies were
fitted to dissocalculation softeware. The kinetic
models used are zero order, first order, Korsmeyer’s,





Where, M/Mt∞ is the fraction of drug released at time
t, k the kinetic constant, and n the release exponent.
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Process Optimization of Ondansetron floating
tablet
 Effect of granule size,
 Effect of drying time & drying
temperature,
 Effect of thickness.
RESULTS & DISCUSSIONS:
Calculation of total dose
IR  = Css x
Vd
F
= 39 ng/ml x 1.9
lit/kg
0.62
= 39 * 10-6 mg/ml
x 1.9 * 103 ml x 60
0.62
=  7.17 mg
Total Dose (TD)
TD = IR [1 + (0.693 x
t/t1/2)]
= 7.17 [1 +
(0.693 x 23/ 4.1)]
= 35 mg.
Drug excipient compatibility study
From the drug excipient compatiblity study, it is
concluded that the given drug ondansetron is
compatible with all excipients.
Measurement of viscocity of polymers
The viscosity of polymer of different grade of HPMC
K4M, HPMC15M & HPMC K100M solution was
measured using Brookfield digital viscometer.
In vitro dissolution profile of factorial batches
The statistical analysis of the factorial design batches
was performed by multiple linear regression analysis
carried out in Microsoft Excel 2003. The data clearly
indicated that the values of Q24hrs, t50%, and f2 were
strongly dependent on the independent variables. The
fitted Equations relating the response Q24hrs, t50%, and
f2 to the transformed factor are shown in following
Equations.
Q24Hrs =88.17 – 3.44 X1 – 12.24 X2 – 0.475 X1X2 –
0.42 X12 – 3.32 X22
(R2 = 0.9965)
t50% = 9.94 + 1.5 X1  + 4.07 X2 - 0.14 X1X2  +0.38
X12 + 1.21 X22
(R2= 0.9935)
f2 = 51.08 + 0.71 X1 - 10.38 X2 –9.13 X1X2 + 3.95
X12 - 2.75 X22
(R2 = 0.8090)
The value of correlation coefficient indicates good fit.
The polynomial Equation can be used to draw
conclusions after considering the magnitude of
coefficient and the mathematical sign it carries, (i.e.
positive or negative).
In case of depended variable Q24hrs, p value for factor
X1 and X2 was found to be 0.0042 and 0.0001
respectively which clearly depicts that the both the
factors i.e content of HPMC and viscosity of HPMC
has individually  influence on drug release. All other
factor has P values greater than 0.005 (p > 0.005).
Thus, it was concluded that the percentage of drug
release depends on both, content and viscosity of
HPMC.
In case of depended variable t50%, p value for factor X2
was found to be 0.0002 which clearly depicts that
factor X2 i.e. viscosity of HPMC has influence on
drug release. All other factor has P values greater than
0.005 (p > 0.005). Thus, it was concluded that the
percent of drug release depends on viscosity of
HPMC.
Comparison of dissolution profiles
In vitro drug release profile of all batches of factorial
design was compared with theoretical drug release
profile. The result shows that Batch N3 (120mg of
HPMC K4M) shown highest f2 value which is 77.33
and it releases the loading dose (18.73%) which is
nearest to theoretical drug release profile (20.48%).
Swelling Index [11]
The swelling index of tablets was determined in 0.1 N
HCl (PH 1.2) at room temperature. The swollen weight
of the tablets was determined at predefined time
intervals. The swelling index was calculated by the
following equation. Determinations were made in
triplicate.
Wt – W0
Swelling index   =
Wt
Where, W0 is the initial weight of tablet, and Wt is the
weight of the tablet at time t.
Physical parameters of prepared tablets [9,12]
All the tablet formulations showed acceptable
pharmacopoeial properties and complied with the in-
house specifications for weight variation, hardness and
friability.
Effect of granule size
So it was clearly seen that the tablets prepared with
20# granules has high porosity. Due to its high
porosity it has the low hardness and thus it has low
floating lag time (35 sec). This batch showed highest
f2 value which is 81.37. So, granules pass through
mesh 20# was kept optimum.
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Effect of drying time & drying temperature
Effect of drying time and drying temperature were not
so much on release of drug. So, 10 min drying time
and 50°C drying temperature were kept optimum.
Effect of tablet thickness
As the thickness of tablet decrease, tablet became
harder and thus friability of the tablets decreases and
drug release is also retarded. So, batch T2 having 3.6
mm thickness of tablet was kept optimum.
*All weights are in mg
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FIG 1 : Drug release profile of factorial batches in
HPMC optimization
FIG 2 : Overlapping Counter plot of content of
NaCMC (X1) and
content of NaHCO3(X2) versus Q24hrs, t50%, f2
CONCLUSION :
A 32 full factorial design was applied to systemically
optimize polymer concentration. The content of
HPMC (X1) and Viscosity of HPMC (X2) were
selected as independent variables. The time required
for 50% drugs released (t50%), Q24hrs, similarity factor f2
were selected as dependent variables. The results of
full factorial design was indicated that the X2 (content
of HPMC) and X2 (Viscosity of HPMC) both have
significant effect on in vitro drug release profile.
Optimized area was obtained with help of counter
plot. From contour plot, it was conclude that HPMC
having content 120 mg and viscosity 5600 cps will
give the satisfactory drug release. The similarity factor
f2 was applied between the in vitro drug release profile
of factorial design batches and theoretical drug release
profile. It was conclude that batch N3 containing
HPMC K4M, 40% was optimize for further work.
From in-vitro buoyancy studies, it was found that
floating lag time of all factorial batches was less than
two minutes. From all above study it was cleared that
process parameters like thickness, granules size,
drying time and drying temperature have great
influence on performance of the floating tablets. So
such parameters are critically maintain or put at their
optimum level during the manufacturing of the
floating tablets to obtained desired properties of
floating tablets, like floating lag time and  floating





A B C D E F G H I
Ondansetron HCl 35 35 35 35 35 35 35 35 35
HPMC K4M 120 120 120 120 120 120 120 120 120
NaCMC 15 15 15 30 30 30 45 45 45
NaHCO3 42 51 60 42 51 60 42 51 60
PVP K-30 20 20 20 20 20 20 20 20 20
IPA q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.
Lactose 59 50 41 44 35 26 29 20 15
Mg-stearate 3 3 3 3 3 3 3 3 3
Talc 6 6 6 6 6 6 6 6 6
Total weight 300 300 300 300 300 300 300 300 300
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